Susanna Naggie, MD

Publications

Fuchs, M, Morgan, TR, Charafeddine, M, Brau, N, Schmidt, WN, Kozal, M, Naggie, S, Cheung, R, Pilot-Matias, T, Yu, Y, Richards, K, Mullally, V, Cohen, DE, Monto, A, and Toro, DH. "An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA." October 2016.

Scholars@Duke

Wyles, D, Brau, N, Naggie, S, Sulkowski, M, Agarwal, K, Patel, K, Afdhal, N, Liu, L, Ding, X, Huang, K-C, Osinusi, A, McNally, J, Brainard, D, Mertens, M, and McHutchison, J. "SOF/VEL single-tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials." October 2016.

Scholars@Duke

Wong, TC, Lan, A, Kiser, JJ, Anderson, PL, Patel, K, Tillman, H, and Naggie, S. "Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression." Hepatology (Baltimore, Md.) 64, no. 3 (September 2016): 999-1000. (Letter)

PMID
26799354
Full Text

Katrak, S, Park, LP, Woods, C, Muir, A, Hicks, C, and Naggie, S. "Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease." Open forum infectious diseases 3, no. 3 (September 2016): ofw173-.

PMID
27704025
Full Text

Clement, ME, Park, LP, Navar, AM, Okeke, NL, Pencina, MJ, Douglas, PS, and Naggie, S. "Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 63, no. 3 (August 2016): 407-413.

PMID
27143663
Full Text

Cooper, C, Naggie, S, Saag, M, Yang, JC, Stamm, LM, Dvory-Sobol, H, Han, L, Pang, PS, McHutchison, JG, Dieterich, D, and Sulkowski, M. "Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 63, no. 4 (August 2016): 528-531.

PMID
27225242
Full Text

Braeu, N, Wyles, D, Kottilil, S, Darr, E, Workowski, K, Luetkemeyer, A, Adeyemi, O, Ruane, P, Doehle, B, Huang, KC, Osinusi, A, McNally, J, Natha, M, Guion, M, McLean, T, Brainard, DM, McHutchison, JG, Naggie, S, and Sulkowski, M. "Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase." July 2016.

Scholars@Duke

Patel, K, Kilfoil, G, Wyles, DL, Naggie, S, Lawitz, E, Bradley, S, Lindell, P, and Suhy, D. "Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)." May 2016.

Scholars@Duke

Bhagani, S, Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Natha, M, Dvory-Sobol, H, McHutchinson, J, Jackson, A, Dieterich, D, and Sulkowski, M. "Retreatment of patients co-infected with HCV and HIV-1 who failed 12 weeks of ledipasvir/sofosbuvir." HIV MEDICINE 17 (April 2016): 38-38.

Scholars@Duke

Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah'moud, MA, Manch, RA, Mohanty, SR, Prabhakar, A, Reindollar, R, Sawyerr, G, Slim, J, Tandon, P, Villadiego, S, and Naggie, S. "Effectiveness of Simeprevir-Containing Regimens Among Patients With." April 2016.

Scholars@Duke

Pages